June 25, 2025
Digital Framework Improves Lung Cancer Screening
Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.
Journal of Clinical Oncology
Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
June 25, 2025
Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.
Journal of Clinical Oncology
June 17, 2025
Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.
Nature
June 5, 2025
Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.
Targeted Oncology
June 4, 2025
Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.
Journal of Clinical Oncology
April 21, 2025
Leading lung cancer specialists discuss revolutionary advances in treating EGFR-mutated non-small cell lung cancer, highlighting how new combination therapies like amivantamab plus chemotherapy are doubling progression-free survival and offering hope for patients with challenging complications like leptomeningeal metastases, while emphasizing practical strategies for managing treatment side effects in community practice.
Oncology News Central
April 16, 2025
Researchers developed RARE-seq, an ultrasensitive blood test detecting cell-free RNA that identifies early-stage lung cancer and monitors treatment resistance.
Nature
February 25, 2025
New drug shrinks HER2-mutant lung cancer tumors in 73% of patients, offering hope for improved treatment options.
MEDPAGE Today
February 21, 2025
Comprehensive review examining molecular mechanisms of cancer invasion and metastasis, identifying potential therapeutic targets for preventing cancer spread.
Nature
February 21, 2025
Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.
Journal of Clinical Oncology
November 4, 2024
Osimertinib after surgery significantly improves survival in early-stage EGFR-mutated NSCLC, reducing cancer recurrence and offering a new standard of care.
Journal of Clinical Oncology
March 8, 2024
The FDA has approved amivantamab for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.
Oncology Learning Network
February 27, 2024
This article reviews strategies for managing treatment resistance in advanced EGFR-mutated lung cancer, focusing on personalization, parsimony, and partnership.
Journal of Clinical Oncology
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.